CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
CymaBay Therapeutics (CBAY) Misses Q4 EPS by 40c
March 18, 2015 4:24 PM EDTCymaBay Therapeutics (NASDAQ: CBAY) reported Q4 EPS of ($0.87), $0.40 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.
... More